TY - JOUR
T1 - Early Levels of Glial Fibrillary Acidic Protein and Neurofilament Light Protein in Predicting the Outcome of Mild Traumatic Brain Injury
AU - Hossain, Iftakher
AU - Mohammadian, Mehrbod
AU - Takala, Riikka S.K.
AU - Tenovuo, Olli
AU - Lagerstedt, Linnéa
AU - Ala-Seppälä, Henna Maria
AU - Frantzén, Janek
AU - van Gils, Mark
AU - Hutchinson, Peter John
AU - Katila, Ari J.
AU - Maanpää, Henna-Riikka
AU - Menon, David
AU - Newcombe, Virginia
AU - Tallus, Jussi
AU - Hrusovsky, Kevin
AU - Wilson, David
AU - Blennow, Kaj
AU - Sanchez, Jean-Charles
AU - Zetterberg, Henrik
AU - Posti, Jussi P.
N1 - Funding Information:
Riikka S.K. Takala has no financial disclosures; RSKT has received speakers fee from Abbott, Fresenius-Kabi, Orion and UCB, conference funding from Pfizer and Steripolar, and is stockholder of Orion. David K. Menon reports collaborative research or consultancy agreements with GlaxoSmithKline Ltd,, Ornim Medical, Shire Medical, Calico Inc., Pfizer Ltd., Pressura Ltd., Glide Pharma Ltd., NeuroTraumaSciences LLC., and Lantasman AB. Virginia F. Newcombe has no financial disclosures. Henrik Zetterberg has served at advisory boards for Roche Diagnostics, Eli Lilly and Wave, has received travel support from Teva, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg. Kaj Blennow has served as a consultant or at advisory boards for Alzheon, BioArctic, Biogen, Eli Lilly, Fujirebio Europe, IBL International, Merck, Novartis, Pfizer, and Roche Diagnostics, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Venture-based platform company at the University of Gothenburg. Jussi P. Posti has no financial disclosures; JPP has received speaker’s fees from Orion corporation and Finnish Medical Association. For the other authors, no financial interests exist.
Funding Information:
This work was partially funded by the European Commission under the 7th Framework Programme (FP7-270259-TBIcare), In-tegra EANS Research Grant (IH), University of Turku Graduate School funding (MM), Government’s Special Financial Transfer tied to academic research in Health Sciences (Finland; JPP), Emil Aaltonen Foundation sr ( JPP), Finnish Brain Foundation sr ( JPP), and NIHR Research Fellowship (PJH). VFJN is funded by an Academy of Medical Sciences/The Health Foundation Clinician Scientist Fellowship. HZ is a Wallenberg Academy Fellow and holds grants from the Swedish and European Research Councils. KB holds the Torsten Söderberg Professorship in Medicine, awarded by the Royal Swedish Academy of Sciences, and holds grants from the Swedish Research Council. The authors thank our research nurses Patricia Bertenyi and Satu Honkala for their valuable contribution to this study.
Publisher Copyright:
Copyright © 2019, Mary Ann Liebert, Inc., publishers 2019.
Copyright:
Copyright 2019 Elsevier B.V., All rights reserved.
PY - 2019/5/15
Y1 - 2019/5/15
N2 - The purpose of this study was to correlate the early levels of glial fibrillary acidic protein (GFAP) and neurofilament light protein (NF-L) with outcome in patients with mild traumatic brain injury (mTBI). A total of 107 patients with mTBI (Glasgow Coma Scale ≥13) who had blood samples for GFAP and NF-L available within 24 h of arrival were included. Patients with mTBI were divided into computed tomography (CT)-positive and CT-negative groups. Glasgow Outcome Scale-Extended (GOSE) was used to assess the outcome. Outcomes were defined as complete (GOSE 8) versus incomplete (GOSE <8), and favorable (GOSE 5-8) versus unfavorable (GOSE 1-4). GFAP and NF-L concentrations in blood were measured using ultrasensitive single molecule array technology. Patients with incomplete recovery had significantly higher levels of NF-L compared with those with complete recovery (p = 0.005). The levels of GFAP and NF-L were significantly higher in patients with unfavorable outcome than in patients with favorable outcome (p = 0.002 for GFAP and p < 0.001 for NF-L). For predicting favorable outcome, the area under the receiver operating characteristic curve for GFAP and NF-L was 0.755 and 0.826, respectively. In a multi-variate logistic regression model, the level of NF-L was still a significant predictor for complete recovery (odds ratio [OR] = 1.008; 95% confidence interval [CI], 1.000-1.016). Moreover, the level of NF-L was a significant predictor for complete recovery in CT-positive patients (OR = 1.009; 95% CI, 1.001-1.016). The early levels of GFAP and NF-L are significantly correlated with the outcome in patients with mTBI. The level of NF-L within 24 h from arrival has a significant predictive value in mTBI also in a multi-variate model.
AB - The purpose of this study was to correlate the early levels of glial fibrillary acidic protein (GFAP) and neurofilament light protein (NF-L) with outcome in patients with mild traumatic brain injury (mTBI). A total of 107 patients with mTBI (Glasgow Coma Scale ≥13) who had blood samples for GFAP and NF-L available within 24 h of arrival were included. Patients with mTBI were divided into computed tomography (CT)-positive and CT-negative groups. Glasgow Outcome Scale-Extended (GOSE) was used to assess the outcome. Outcomes were defined as complete (GOSE 8) versus incomplete (GOSE <8), and favorable (GOSE 5-8) versus unfavorable (GOSE 1-4). GFAP and NF-L concentrations in blood were measured using ultrasensitive single molecule array technology. Patients with incomplete recovery had significantly higher levels of NF-L compared with those with complete recovery (p = 0.005). The levels of GFAP and NF-L were significantly higher in patients with unfavorable outcome than in patients with favorable outcome (p = 0.002 for GFAP and p < 0.001 for NF-L). For predicting favorable outcome, the area under the receiver operating characteristic curve for GFAP and NF-L was 0.755 and 0.826, respectively. In a multi-variate logistic regression model, the level of NF-L was still a significant predictor for complete recovery (odds ratio [OR] = 1.008; 95% confidence interval [CI], 1.000-1.016). Moreover, the level of NF-L was a significant predictor for complete recovery in CT-positive patients (OR = 1.009; 95% CI, 1.001-1.016). The early levels of GFAP and NF-L are significantly correlated with the outcome in patients with mTBI. The level of NF-L within 24 h from arrival has a significant predictive value in mTBI also in a multi-variate model.
KW - biomarkes
KW - traumatic brain injury
KW - outcome measures
UR - http://www.scopus.com/inward/record.url?scp=85065528940&partnerID=8YFLogxK
U2 - 10.1089/NEU.2018.5952
DO - 10.1089/NEU.2018.5952
M3 - Article
SN - 0897-7151
VL - 36
SP - 1551
EP - 1560
JO - Journal of Neurotrauma
JF - Journal of Neurotrauma
IS - 10
ER -